Pharmaceuticals
News Category
VERAXA Biotech Advances Lead BiTAC T-Cell Engager with Cell Line Development Partnership
VERAXA Biotech has initiated cell line development for its lead BiTAC T-cell engager program, partnering with ATUM to advance toward IND/CTA-enabling ...
Sustained Release Polymers Market Poised to Reach USD 7.8 Billion by 2036, Driven by Chronic Disease Management and Advanced Drug Delivery
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by rising...
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026
VERAXA Biotech reported progress in its BiTAC platform and growing pharma interest, planning to prioritize BiTAC programs while monetizing non-BiTAC a...
VERAXA Biotech Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program
VERAXA Biotech has begun cell line development for its BiTAC T-cell engager therapy, aiming to improve tumor selectivity and reduce toxicity in cancer...
VERAXA Biotech AG Targets Antibody Therapeutics Deals as Sector Activity Surges
The article highlights strong deal activity in antibody-drug conjugates and T-cell engagers, positioning VERAXA Biotech AG's platform for potential st...
Ace Therapeutics Launches Comprehensive Preclinical Analgesic Drug Development Services
Ace Therapeutics announces end-to-end preclinical services for pain therapeutics, including diverse in vivo pain models and a full research platform, ...
Medios AG Closes Aschaffenburg Facility to Optimize Manufacturing Network Amid Margin Pressure
Medios AG is closing its Aschaffenburg facility and consolidating patient-specific manufacturing to improve efficiency, affecting 32 employees, as the...
Helus Pharma Reports Fiscal 2026 Results, Phase 3 Trial for Depression on Track
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003 in major depressive disorder, with topline data expe...
Voyageur Pharmaceuticals Taps Fluor for Feasibility Studies on Iodine Production and Integrated Contrast Drug Facility
Voyageur Pharmaceuticals engages Fluor Corporation to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated cont...
Knight Therapeutics Repays $60 Million Credit Facility Used for Paladin Acquisition
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using strong operational cash...
Voyageur Pharmaceuticals Evaluates Three U.S. Sites for Integrated Contrast Media Manufacturing Facility, Targeting Cost Leadership and Supply Chain Security
Voyageur Pharmaceuticals is evaluating three U.S. sites for a vertically integrated iodine and barium contrast media facility, aiming to reduce costs ...
Earth Science Tech Inc. Positions Itself at the Intersection of Telemedicine, Pharmacy, and Healthcare Services
Earth Science Tech Inc. has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emphasizing...
Voyageur Pharmaceuticals Submits Exploration Permit for Frances Creek Barite Project, Advancing Toward Feasibility Study
Voyageur Pharmaceuticals has applied for a multi-year exploration permit at its Frances Creek barite project, aiming to conduct bulk sampling and geot...
Voyageur Pharmaceuticals Closes $5 Million Private Placement for Barium and Iodine Contrast Media Development
Voyageur Pharmaceuticals raised $5 million through a private placement to fund FDA licensing, regulatory approvals, and project development for its ba...
Kairos Pharma Announces Pipeline Expansion and Clinical Milestones in Mid-Year Update
Kairos Pharma Ltd. provided a mid-year update highlighting plans to acquire worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor, a...
Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities on BioMedWire Podcast
Quantum BioPharma’s co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial progress of unbuzzd, emphasizing upcoming...
Quantum BioPharma: A Diversified Biotech Firm Advancing MS Therapy and Consumer Wellness Products
Quantum BioPharma Ltd. (NASDAQ: QNTM) is highlighted as a company to watch due to its differentiated multiple sclerosis program targeting demyelinatio...
Redwood AI Corp. Gains DTC Eligibility, Engages IBN for Investor Awareness Campaign
Redwood AI Corp. announced DTC eligibility for its common shares, simplifying U.S. trading and enhancing liquidity, while engaging IBN for investor aw...
Carmed Pharmaceuticals Highlights CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is expanding into the U.S. market, leveragin...
Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Discovery
Sino Biological's new XPressMAX™ Cell-Free Protein Synthesis Kit enables ultra-fast protein synthesis in 3 hours, integrating with AI-driven screening...
NanoViricides Advances Broad-Spectrum Antiviral NV-387 Toward Phase II Trials for MPox
NanoViricides reports progress in developing NV-387, a broad-spectrum antiviral, with regulatory approval for Phase II MPox trials in the DRC and FDA ...
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Development
NanoViricides has secured $2 million through a registered direct offering with an institutional investor, providing capital to support its clinical-st...
Lantern Pharma Raises $4.4 Million in Registered Direct Offering to Advance AI-Driven Oncology Pipeline
Lantern Pharma closed a $4.4 million registered direct offering, with potential additional proceeds from warrants, to support its precision oncology p...
Tonix Pharmaceuticals to Present at Two Key Investor Conferences in May
Tonix Pharmaceuticals (NASDAQ: TNXP) will showcase its CNS and immunology pipeline at the RBC Capital Markets Global Healthcare Conference and A.G.P.’...
Lantern Pharma Expands predictBBB into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model, enabling real-time molecular intelligence for drug ...
LIXTE Biotechnology’s LB-100 Poised to Transform Cancer Treatment by Enhancing Chemo and Immunotherapy
LIXTE Biotechnology’s first-in-class PP2A inhibitor LB-100 is advancing through clinical trials for solid tumors with high unmet need, offering a nove...
Soligenix Leverages Platform Technology to Streamline Drug Development Across Multiple Indications
Soligenix's use of synthetic hypericin for multiple dermatologic conditions exemplifies how platform-based drug development can reduce redundancy and ...
PolyPeptide Shareholders Approve All Proposals at 2026 Annual General Meeting
PolyPeptide Group AG held its fifth annual general meeting, where shareholders approved all board proposals, including re-election of directors and au...
LIXTE Biotechnology Holdings Files 2025 Form 10-K, Highlighting Transformational Year with Clinical Progress and Strategic Expansion
LIXTE Biotechnology Holdings (NASDAQ: LIXT) filed its 2025 Annual Report on Form 10-K, detailing a year of leadership changes, clinical advancement of...
LIXTE Biotechnology Holds World’s Only Clinical-Stage PP2A Inhibitor, Promising New Cancer Treatment Paradigm
LIXTE Biotechnology’s LB-100, the first and only clinical-stage PP2A inhibitor, could enhance cancer treatment by sensitizing tumors to immunotherapy ...
Lonza Nominates Stephen Fry as Independent Board Member
Lonza nominates former Eli Lilly executive Stephen Fry to its board, bringing expertise in organizational transformation and performance culture to su...
Voyageur Pharmaceuticals Advances Barium and Iodine Contrast Media Projects, Targeting North American Supply Chain Security
Voyageur Pharmaceuticals is progressing its vertically integrated barium and iodine contrast media projects, including bankable feasibility studies an...
Soligenix Secures Key European Milestone for Dusquetide Development in Behçet's Disease
Soligenix received a positive opinion from the EMA's Committee for Orphan Medicinal Products for dusquetide in Behçet's disease, unlocking development...
Netherton Syndrome Awareness Campaign Surpasses 2 Million Video Views, Highlighting Rare Disease Day 2026
Quoin Pharmaceuticals' NETHERTON NOW campaign has generated nearly 2 million video views and 24 million impressions, amplifying awareness of Netherton...
Oncotelic Therapeutics Featured in BioMedWire Editorial on Late-Stage Biotech M&A Trends
Oncotelic Therapeutics is highlighted in a BioMedWire editorial examining the increasing M&A focus on de-risked, late-stage oncology and CNS assets, p...
Helus Pharma Phase 2a SPL026 Data Published in Nature Medicine Shows Significant Reduction in Depressive Symptoms
Helus Pharma reported that a single dose of SPL026 achieved statistically significant and clinically meaningful reductions in depressive symptoms vers...